<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121180">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02108171</url>
  </required_header>
  <id_info>
    <org_study_id>GZFPH-IRB-2013-086</org_study_id>
    <nct_id>NCT02108171</nct_id>
  </id_info>
  <brief_title>Intranasal Dexmedetomidine Premedication</brief_title>
  <official_title>A Randomised Controlled Trial of Intranasal Dexmedetomidine as Premedication for Suspension Laryngoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou First Municipal People’s Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou First Municipal People’s Hospital</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Most patients with preoperative varying degrees of stress, anxiety, which makes the stress
      response in patients and affect the normal conduct of anesthesia and surgery.The sympathetic
      system hyperexcitability prone to cause adverse cardiovascular events and affect
      postoperative recovery. However, phenobarbital, as the traditional premedication, has less
      sedative, weak anxiolytic and other shortcomings. Midazolam accompanied by inhibition of
      respiration,excessive sedation, easily induced delirium,prolonged recovery time and so on.
      Dexmedetomidine is a highly selective α2-adrenergic receptor agonist, it has sedative,
      anxiolytic, no inhibition of respiration, and also colorless, odorless, non-mucosal
      stimulation, nasal drip ease of administration, patient acceptance, comfortable. Therefore,
      dexmedetomidine as premedication has certain advantages. The purpose of this research is to
      study sedative effect, safety and the impact of anesthesia recovery period of intranasal
      dexmedetomidine premedication for suspension laryngoscopy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients received intranasal dexmedetomidine (1μg.kg-1) or placebo at approximately 45
      min before induction of anesthesia.The study drug was prepared in a 1-ml syringe.An equal
      volume of dexmedetomidine or placebo was dropped into each nostril by a blinded research
      assistant in the supine position.Automatic sphygmomanometer measure blood pressure.Oxygen
      saturation and heart rate were measured by a pulse oximeter. Respiratory rate, sedation
      score and anxiety levels regularly assessed. Patients with general anesthesia, suspension
      laryngoscopy surgery and postoperative care, standard monitoring are unified.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Extubation time after intranasal dexmedetomidine premedication</measure>
    <time_frame>1 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The time from the end of surgery to extubation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sedation level</measure>
    <time_frame>1 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Sedation level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The occurrence of perioperative adverse events</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The occurrence of perioperative adverse events:1) hypotension, 2) hypertension, 3) bradycardia, 4) tachycardia, 5) the occurrence of postoperative shivering, 6) postoperative nausea and vomiting, 7) for pain and analgesic demand, 8) intraoperative awareness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic responses</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Hemodynamic responses to intubation and extubation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The over-all satisfaction of patients</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>the over-all satisfaction of patients with anesthesia and surgery</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Benign Neoplasm of Vocal Fold - Glottis</condition>
  <arm_group>
    <arm_group_label>dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intranasal dexmedetomidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intranasal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>intranasal dexmedetomidine 1μg.kg-1，0.9% saline was added to make a final volume of 1 mL.all patients received intranasal medication  at approximately 45-60 min before induction of anesthesia.</description>
    <arm_group_label>dexmedetomidine</arm_group_label>
    <other_name>intranasal dexmedetomidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>0.9% saline 1 mL all patients received intranasal medication at approximately 45-60 min before induction of anesthesia.</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Surgery:The laryngoscope vocal polyp excision

          -  Aged 18 to 60 years old

          -  Body mass index (BMI) &lt; 30 kg/m2

          -  American society of Anesthesiologist (ASA) I -II

        Exclusion Criteria:

          -  The investigator refused to participate

          -  Known allergy or hypersensitive reaction to dexmedetomidine or anesthetic

          -  With previous history of heart disease

          -  Pregnant women; no reliable contraceptive measures in postmenopausal women

          -  Preoperative heart rate less than 45bpm; Ⅱ or Ⅲ degree atrioventricular block;
             ischemic heart disease

          -  Taking antihypertensive drugs such as methyldopa, clonidine and other α2 receptor
             agonist

          -  Asthma

          -  Sleep apnea syndrome

          -  Liver and kidney dysfunction

          -  Known to suffer from mental illness

          -  Long-term use of sedatives and analgesics in patients
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiangcai Ruan, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangzhou First Municipal People's Hospital,Guangzhou Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiangcai Ruan, MD,PHD</last_name>
    <phone>+8620-81048306</phone>
    <email>xc_ruan@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chengxiang Lu, MD, Msc</last_name>
    <phone>+8620-81048310</phone>
    <email>lcxhcn2007@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangzhou First Municipal People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510180</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guangzhou First Municipal People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <zip>510180</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiangcai Ruan</last_name>
      <phone>8620-81048306</phone>
      <email>xc_ruan@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Chengxiangcai Lu</last_name>
      <phone>8620-81048310</phone>
      <email>lcxhcn2007@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xiangcai Ruan</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chengxiang Lu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yuan Lin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Sheta SA, Al-Sarheed MA, Abdelhalim AA. Intranasal dexmedetomidine vs midazolam for premedication in children undergoing complete dental rehabilitation: a double-blinded randomized controlled trial. Paediatr Anaesth. 2014 Feb;24(2):181-9. doi: 10.1111/pan.12287. Epub 2013 Nov 15.</citation>
    <PMID>24237879</PMID>
  </reference>
  <reference>
    <citation>Yuen VM, Irwin MG, Hui TW, Yuen MK, Lee LH. A double-blind, crossover assessment of the sedative and analgesic effects of intranasal dexmedetomidine. Anesth Analg. 2007 Aug;105(2):374-80.</citation>
    <PMID>17646493</PMID>
  </reference>
  <reference>
    <citation>Yuen VM, Hui TW, Irwin MG, Yao TJ, Chan L, Wong GL, Shahnaz Hasan M, Shariffuddin II. A randomised comparison of two intranasal dexmedetomidine doses for premedication in children. Anaesthesia. 2012 Nov;67(11):1210-6. doi: 10.1111/j.1365-2044.2012.07309.x. Epub 2012 Sep 5.</citation>
    <PMID>22950484</PMID>
  </reference>
  <reference>
    <citation>Cheung CW, Ng KF, Liu J, Yuen MY, Ho MH, Irwin MG. Analgesic and sedative effects of intranasal dexmedetomidine in third molar surgery under local anaesthesia. Br J Anaesth. 2011 Sep;107(3):430-7. doi: 10.1093/bja/aer164. Epub 2011 Jun 16.</citation>
    <PMID>21685111</PMID>
  </reference>
  <reference>
    <citation>Iirola T, Vilo S, Manner T, Aantaa R, Lahtinen M, Scheinin M, Olkkola KT. Bioavailability of dexmedetomidine after intranasal administration. Eur J Clin Pharmacol. 2011 Aug;67(8):825-31. doi: 10.1007/s00228-011-1002-y. Epub 2011 Feb 12.</citation>
    <PMID>21318594</PMID>
  </reference>
  <reference>
    <citation>Nooh N, Sheta SA, Abdullah WA, Abdelhalim AA. Intranasal atomized dexmedetomidine for sedation during third molar extraction. Int J Oral Maxillofac Surg. 2013 Jul;42(7):857-62. doi: 10.1016/j.ijom.2013.02.003. Epub 2013 Mar 14.</citation>
    <PMID>23497981</PMID>
  </reference>
  <reference>
    <citation>Ambi US, Joshi C, Ganeshnavar A, Adarsh E. Intranasal dexmedetomidine for paediatric sedation for diagnostic magnetic resonance imaging studies. Indian J Anaesth. 2012 Nov;56(6):587-8. doi: 10.4103/0019-5049.104588.</citation>
    <PMID>23325950</PMID>
  </reference>
  <reference>
    <citation>Yuen VM, Hui TW, Irwin MG, Yao TJ, Wong GL, Yuen MK. Optimal timing for the administration of intranasal dexmedetomidine for premedication in children. Anaesthesia. 2010 Sep;65(9):922-9. doi: 10.1111/j.1365-2044.2010.06453.x. PubMed PMID: 20645951.</citation>
    <PMID>20645951</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 5, 2014</lastchanged_date>
  <firstreceived_date>March 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou First Municipal People's Hospital</investigator_affiliation>
    <investigator_full_name>Xiangcai Ruan</investigator_full_name>
    <investigator_title>Vice Chair</investigator_title>
  </responsible_party>
  <keyword>intranasal</keyword>
  <keyword>dexmedetomidine</keyword>
  <keyword>early recovery</keyword>
  <keyword>suspension laryngoscopy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
